www.healio.com ·
what clinicians need to know about alzheimers disease biomarkers
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article discusses clinical guidelines for Alzheimer's blood biomarker tests, which may increase adoption of these tests in diagnostics and clinical trials. Commercial impact is indirect: potential revenue growth for diagnostic companies (Fujirebio/Lumipulse, Roche) and expanded market for Alzheimer's therapeutics. No immediate price or supply chain disruption; mechanism is regulatory/guideline-driven adoption. Sector impact is weak and long-term; no concrete investment or price moves reported.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Alzheimer's Association published guidelines for blood biomarker tests (plasma p-tau217).
- Two blood-based tests received FDA clearance: Lumipulse G p-tau217/Amyloid 1-42 and Roche Elecsys p-tau181.
- Guidelines recommend high-sensitivity BBM tests for patients with cognitive impairment in specialized care.
- Guidelines emphasize shared decision-making before testing.
- Published in Journal of the Alzheimer Association on 2026-05-07.